medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Number 2

<< Back Next >>

Rev Latin Infect Pediatr 2018; 31 (2)

Excerpt from the «Guide of the Spanish Society of Pediatric Infectious Diseases on prevention, diagnosis and treatment of neonatal infection with herpes simplex virus»

Prieto TLM, Ramos AJT, González TMI, Alarcón AA, Fernández MMC, Goncé MA, Frick MA, Noguera JA, Moreno PD, Baquero AF

Language: Spanish
References: 16
Page: 48-53
PDF size: 342.07 Kb.


ABSTRACT

Neonatal herpes simplex virus infections are rare, but are associated with significant morbidity and mortality. Most newborns acquire herpes simplex virus infection in the peripartum period. For peripartum transmission to occur, women must be shedding the virus in their genital tracts symptomatically or asymptomatically around the time of delivery. There are evidence-based interventions in pregnancy to prevent the transmission to the newborn. Caesarean section should be performed in the presence of herpetic lesions, and antiviral prophylaxis in the last weeks of pregnancy is recommended to suppress genital tract herpes simplex virus at the time of delivery. The diagnosis and early treatment of neonatal herpes simplex virus infections require a high index of suspicion, especially in the absence of skin lesions. It is recommended to rule out herpes simplex virus infections in those newborns with mucocutaneous lesions, central nervous system involvement, or septic appearance. The prognosis of newborns with skin, eye, and/or mouth disease in the high-dose acyclovir era is very good. Antiviral treatment not only improves mortality rates in disseminated and central nervous system disease, but also improves the rates of long-term neurodevelopmental impairment in the cases of disseminated disease. Interestingly, a 6-month suppressive course of oral acyclovir following the acute infection has improved the neurodevelopmental prognosis in patients with CNS involvement.


REFERENCES

  1. Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex type 2 infections in 2012. PLoS ONE. 2015; 10 (1): e114989.

  2. Gnann JW Jr., Whitley RJ. Genital herpes. N Engl J Med. 2016; 375: 666-674.

  3. James SH, Kimberlin DW. Neonatal herpes simplex virus infection. Infect Dis Clin North Am. 2015; 29 (3): 391-400.

  4. Pinninti SG, Kimberlin DW. Management of neonatal herpes simplex virus infection and exposure. Arch Dis Child Fetal Neonatal Ed. 2014; 99 (3): F240-244.

  5. Jones CA, Raynes-Greenow C, Isaacs D; Neonatal HSV Study Investigators and Contributors to the Australian Paediatric Surveillance Unit. Population-based surveillance of neonatal herpes simplex virus infection in Australia, 1997-2011. Clin Infect Dis. 2014; 59 (4): 525-531.

  6. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003; 289 (2): 203-209.

  7. Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. Pediatr Infect Dis J. 2011; 30 (2): 153-157.

  8. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med. 1991; 324: 450-454.

  9. Kimberlin DW, Lin CY, Jacobs RF, Frenkel LM, Gruber WC, Rathore M et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001; 108 (2): 223-229.

  10. Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics. 1980; 66 (4): 489-494.

  11. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996; 174 (6): 1162.

  12. Cantey JB, Mejías A, Wallihan R, Doern C, Brock E, Salamon D et al. Use of blood polymerase chain reaction testing for diagnosis of herpes simplex virus infection. J Pediatr. 2012; 161 (2): 357-361.

  13. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001; 108 (2): 230-238.

  14. Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, Ahmed A et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med. 2011; 365: 1284-1292.

  15. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev. 2008; 1: CD004946.

  16. Kimberlin DW, Baley J, Committee of infectious diseases, Committee of fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 2013; 131 (2): e635-646.




2020     |     www.medigraphic.com